Compare Valero Energy Corporation (VLO) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Valero Energy Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Valero Energy Corporation trades at $389.25 (market cap $110.23B), while State Street SPDR S&P Biotech ETF trades at $159.9. The key difference: Valero Energy Corporation pays a 1.25% dividend while State Street SPDR S&P Biotech ETF pays none, and Valero Energy Corporation is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals.
| VLO | XBI | |
|---|---|---|
Market Cap | $110.23B | — |
Sector | Energy | Broad Market / Factor |
52-Week High | $388.95 | $169.55 |
52-Week Low | $156.39 | $93.43 |
Enterprise Value | $113.71B | — |
Dividend Yield | 1.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Valero Energy (VLO) trades at $382.85, up 3.27% today, reflecting strong momentum amid favorable refining conditions. The stock exhibits a bullish technical trend, with recent earnings beats and a Zacks Rank #1 (Strong Buy) as of September 9, 2026. Fundamentals show robust profitability with a 29.31% ROE, though revenue has declined from $176.4B in 2022 to $122.7B in 2025. Analyst consensus is bullish with a $345.55 price target, and the company maintains a solid balance sheet with $4.66B in cash.
VLO's outlook is supported by tight fuel supplies and healthy demand, with projected 2026 net income of $7.2B. Key risks include volatile energy prices and potential regulatory pressures. The stock offers growth potential but faces headwinds from revenue declines and geopolitical factors affecting the energy sector.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
